MCP-ratiopharm

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of MCP-ratiopharm

MCP-ratiopharm is a brand-name medication whose active ingredient is metoclopramide hydrochloride. It is a synthetic compound belonging to a group of medicines known as dopamine receptor antagonists and is classified as a prokinetic agent. The brand is manufactured by ratiopharm GmbH and is primarily distributed in European markets.

Quick Facts

Property Description
Active ingredient Metoclopramide hydrochloride
Form Primarily tablets or oral solution
Pharmacological Class Prokinetic, Dopamine Antagonist
General Purpose Managing nausea, vomiting, and gastric motility issues
Rx/OTC Status Prescription-Only (Rx)

Metoclopramide is clinically recognized for its dual action: it possesses both antiemetic (anti-vomiting) and gastroprokinetic (stomach-motility-enhancing) properties. Its effectiveness in accelerating the transit of food from the stomach to the small intestine, and thereby relieving symptoms of delayed gastric emptying (gastroparesis), is supported by pharmacological studies.

Metoclopramide is classified as a centrally and peripherally acting anti-emetic drug, emphasizing its role in both the nervous system and the digestive tract. The MCP-ratiopharm formulation is typically used for the short-term management of acute conditions, such as preventing nausea and vomiting caused by chemotherapy or relieving symptoms associated with specific gastric motility disorders.

Regulatory References

  1. Metoclopramide-containing medicines - referral
Advertisements

What side effects are possible with MCP-ratiopharm?

Possible Side Effects and Safety Information

The safety profile for MCP-ratiopharm, which contains metoclopramide, is officially categorized by governmental regulatory bodies. The most notable adverse reactions are related to the Nervous System, which are classified by frequency.


Adverse Reaction Classifications

Classification Examples of Reactions
Very Common Somnolence (drowsiness).
Common Extrapyramidal disorders (involuntary movements, like parkinsonism or akathisia), asthenia (loss of strength), diarrhoea, depression, and hypotension.
Uncommon Dystonia, bradycardia (slow heart rate), hyperprolactinaemia, and hypersensitivity reactions.
Rare Convulsion (seizures), confusional state, and galactorrhoea (abnormal milk production).

Serious Safety Considerations

The regulatory labeling includes warnings for potentially serious conditions, most critically Tardive Dyskinesia (TD), a movement disorder that may be irreversible. The risk of TD is directly related to the duration of treatment and the cumulative dose. Other serious reactions documented include Neuroleptic Malignant Syndrome (NMS) and serious cardiovascular events (e.g., cardiac arrest, QT prolongation), particularly following intravenous administration.

Population and Duration-Related Safety

Official safety documents note that extrapyramidal disorders occur more frequently in children and young adults. The risk of TD is higher in the older adult population. The risk of accumulation necessitates that a dose reduction is officially recommended for patients with renal or severe hepatic impairment. Due to duration-related risk, regulatory agencies restrict the treatment length, for instance, not exceeding 12 weeks.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation defines the clinical presentation of overexposure to metoclopramide hydrochloride based on specific manifestations and associated severe outcomes. Overdose may present with Central Nervous System effects, including drowsiness, confusion, seizures, and Extrapyramidal Disorders, which are characterized by involuntary movement disturbances. Gastrointestinal effects such as diarrhea are also documented.

Severe Outcomes and Emergency Actions

Severe and life-threatening outcomes are officially recognized, particularly cardiovascular events such as circulatory collapse, severe bradycardia, and cardiac arrest. The risk of Methemoglobinemia is also documented. Due to these risks, official labeling requires individuals to seek immediate medical attention or contact the poison control helpline when overdose is suspected or symptoms are apparent.

Treatment is primarily supportive and symptomatic. Anticholinergic or antiparkinsonian medicines are documented as interventions to manage Extrapyramidal Reactions. While there is no specific antidote for metoclopramide itself, methylene blue is a documented intervention for Methemoglobinemia. Symptoms are often self-limiting and may resolve within twenty-four hours.

Population Considerations

Regulatory documentation notes that infants and children are more susceptible to Extrapyramidal Disorders following overexposure. Neonates are specifically documented to be at increased risk for developing Methemoglobinemia in the event of an overdose.

Advertisements

Therapeutic Uses of MCP-ratiopharm

What MCP-ratiopharm Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed, focusing primarily on relieving symptoms related to heightened physiological activity in the upper digestive system. It is commonly used in situations involving certain distressing symptoms that interfere with daily comfort.

Metoclopramide is relevant in contexts marked by increased discomfort or tension, specifically for nausea and vomiting. This use is applied in clinical settings that involve acute or unstable symptom patterns. The medication is applied in addressing symptom clusters that may become intense or disruptive, such as the urgent feeling of sickness and the act of vomiting.

Common indications where this medication is used include sickness related to challenging treatments like chemotherapy or radiotherapy, migraine episodes, and symptoms of slow stomach emptying. The supportive relief it offers contributes to easing the overall symptom burden.

Quick Fact: Relief for Nausea

The medication is applied in scenarios where symptomatic assistance is needed to address acute or episodic nausea and vomiting.

Regulatory References

  1. European Medicines Agency (EMA) therapeutic overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use MCP-ratiopharm?

The population eligibility for metoclopramide is strictly defined by regulatory authorities, classifying users into permitted, restricted, or prohibited groups. The medicine is primarily approved for adults (18 years and over) for its labeled uses.

Absolute Contraindications (Must Not Use)

Use is contraindicated in patients with specific severe health conditions or concurrent treatments, as stated in the prescribing information:

  • Children less than 1 year of age.
  • Gastrointestinal Haemorrhage, Mechanical Obstruction, or Perforation.
  • Phaeochromocytoma (confirmed or suspected).
  • Epilepsy or Parkinson's Disease.
  • History of Tardive Dyskinesia (metoclopramide-induced).
  • Concurrent use of Levodopa or Dopaminergic Agonists.

Restricted and Conditional Use

Certain populations require special consideration or dose adjustment to establish eligibility:

  • Severe Renal or Hepatic Impairment: Requires a mandatory dose reduction to avoid drug accumulation.
  • Children and Adolescents (1–18 years): Use is generally restricted to specific indications, such as secondary prevention of chemotherapy-induced nausea, and is limited in duration.
  • Pregnancy and Lactation: Use is not recommended during breastfeeding. While it can be used during pregnancy if clinically needed, avoidance is advised near the end of pregnancy.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metoclopramide hydrochloride, the active ingredient in MCP-ratiopharm, has formally documented interaction patterns that are defined by regulatory authorities. These interactions are categorized based on their mechanism and resulting constraints on co-administration.


Official Interaction Restrictions

The co-administration of this medication with levodopa or other dopaminergic agonists is formally classified as a contraindicated combination due to pharmacodynamic antagonism. Combination with alcohol or other Central Nervous System (CNS) depressants is also restricted, as it results in the potentiation of sedative effects, an additive pharmacodynamic outcome.


Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance Category Official Interaction Outcome
Strong CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine) Co-administration leads to increased metoclopramide plasma concentration (pharmacokinetic interaction).
Neuroleptics/Antipsychotics May result in an additive risk of Extrapyramidal Disorders (pharmacodynamic interaction).
Cyclosporine and Digoxin Metoclopramide alters the bioavailability of these drugs, necessitating careful plasma concentration monitoring (prokinetic effect).
Oral Drugs with GI Absorption Accelerated gastric emptying may enhance or diminish the absorption of other oral medications (e.g., paracetamol).

Population-Specific Constraints

Regulatory documents note that patients with renal impairment (creatinine clearance le 60 mL/minute) or hepatic impairment (Child-Pugh B or C) experience reduced clearance of metoclopramide. This results in drug accumulation, which increases exposure and requires specific considerations outlined in the official labeling.

Advertisements

Mechanism of Action

MCP-ratiopharm, which contains the active substance metoclopramide, exerts its action through two distinct mechanisms involving neurotransmitter receptor systems in the central and peripheral nervous systems.

Modulation of Dopamine Receptor Signaling

Metoclopramide acts as an antagonist by blocking D2-dopamine receptors, primarily in the chemoreceptor trigger zone of the central nervous system. This receptor-mediated signaling event results in the reduction of dopamine influence on the targeted pathway.


Enhancement of Serotonin Receptor Activity

Concurrently, the drug acts as an agonist on 5-HT4 (serotonin) receptors located within the enteric nervous system of the gastrointestinal tract. This interaction initiates a signaling cascade that increases the release of acetylcholine at nerve endings, a mechanism that modulates muscle contraction.


System-Level Physiological Modulation

This dual-receptor activity results in system-level physiological adjustments by directly enhancing the tone and amplitude of gastric contractions. The molecular events lead to accelerated gastric emptying and decreased transit time through the small intestine, promoting increased coordination of movement within the upper digestive tract.

Advertisements

Dosage and Administration Information

How to Use MCP-ratiopharm

This section outlines the general principles and administration constraints for metoclopramide, the active ingredient in MCP-ratiopharm.

Administration Routes and Scheduling

Metoclopramide is administered via the oral route (tablets or solution) and through parenteral routes (intravenous or intramuscular injection) in clinical settings. The typical adult dose is 10 mg per administration. To maintain consistent use patterns and prevent accumulation, a minimal interval of 6 hours must be respected between any two doses, even if the preceding dose was ineffective or rejected.

Oral forms, when prescribed multiple times daily, are generally instructed to be taken on an empty stomach, specifically 30 minutes before each meal and at bedtime.

Duration and Dosage Adjustments

Therapy with metoclopramide is strictly time-limited. For acute conditions, the treatment duration should typically not exceed 5 days. For some specific chronic conditions, such as gastroparesis, therapy is typically limited to a maximum of 12 weeks.

Dosing regimens require modification in certain patient populations. In cases of severe renal or hepatic impairment, a dose reduction of 50% or more is indicated to account for altered elimination, which prevents potential accumulation. For intravenous use, the dose must be administered as a slow injection over a minimum of three minutes.

Advertisements

Recent Clinical Evidence

The body of research on metoclopramide, the active ingredient in MCP-ratiopharm, is categorized by the specific conditions that research has explored. This overview describes the types of research conducted, the outcomes monitored, and what research gaps or limitations remain documented, strictly based on official scientific and regulatory findings.


Evidence for Use in Chemotherapy-Induced Nausea and Vomiting (CINV)

Research utilized short-term Randomized Controlled Trials (RCTs) that explored how symptoms evolved following chemotherapy. These studies were conducted during periods of increased symptom activity and research examined outcomes related to measuring physical discomfort from vomiting and the intensity of nausea.

Early research examined historical high-dose regimens and reported patterns related to the management of vomiting during the delayed phase (days 2–5), specifically monitoring a specific endpoint, such as the absence of symptoms. Regulatory decisions have led to restrictions on the use of these historical high-dose regimens, meaning those findings now reflect a specific, non-current context. A key documented research gap is the limited nature of comparative evidence against newer, standard treatments for acute CINV.


Evidence for Use in Postoperative Nausea and Vomiting (PONV) and Acute Migraine

Postoperative Nausea and Vomiting (PONV)

The research utilized RCTs and Systematic Reviews conducted in populations of adults and children. Studies monitored outcomes related to preventing acute episodes of vomiting and nausea in the immediate post-operative period. Findings described patterns observed in the studies that contribute to the broader evidence base for post-operative management.

Acute Migraine-Associated Nausea and Vomiting

Research was applied in studies examining short-term, acute migraine episodes. These trials explored the effect on outcomes describing episodic or acute changes in nausea intensity. Studies reported patterns related to the management of nausea in the acute setting. Evidence quality varies across studies for both indications, and for PONV, there is limited information for the specific anti-nausea effect separate from preventing vomiting.


Long-Term Outcomes and Follow-up Duration in Research

Across most indications, studies exploring short-term symptom changes focused on very short-term outcomes (ranging from a few hours to five days). The regulatory conclusion is that there is limited information for long-term outcomes, leading to mandatory restrictions that limit use to a short duration (e.g., maximum 12 weeks), as long-term effects are not fully established. Data for certain groups remain insufficient to support sustained use.

Key Studies & References

  1. Efficacy of current antiemetic treatments for preventing delayed chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials
  2. What medical therapies work for gastroparesis? (Review of Crossover Trials and Evidence Gaps)
  3. CCLG guideline on the management of chemotherapy induced nausea and vomiting (Pediatric Guidelines)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about MCP-ratiopharm (FAQ)

Q: What are the possible signs of Tardive Dyskinesia (TD) associated with this medicine?

Regulatory labeling states that the movement disorder Tardive Dyskinesia (TD) is a serious risk associated with this medicine, especially with longer use. Signs of TD may include involuntary, uncontrolled movements of the face and tongue, such as lip smacking or cheek puffing. Uncontrolled movements of the arms and legs have also been described in official product information.

Q: Are there specific over-the-counter medicines that should not be taken with MCP-ratiopharm?

Official product information advises caution when combining MCP-ratiopharm with other drugs that depress the central nervous system (CNS). This may include certain over-the-counter sedatives, sleeping aids, or pain relievers. Combining these can lead to an increased risk of drowsiness or severe sedation, according to regulatory guidance.

Q: What happens if a patient forgets to take a scheduled dose?

According to the official instructions for use, the most critical rule is to respect a minimal interval of six hours between any two doses. This six-hour minimum interval is maintained according to official instructions, even if a previous dose was missed or rejected (vomited). This constraint is in place to prevent drug accumulation in the body.

Q: Are there any signs of a very serious reaction called Neuroleptic Malignant Syndrome (NMS) to watch for?

Official safety labeling includes warnings about the potential for a rare but serious condition called Neuroleptic Malignant Syndrome (NMS). NMS is characterized by a combination of symptoms such as high fever, severe muscle stiffness, and mental changes like confusion. Changes in pulse or blood pressure are also noted in the documentation as part of this syndrome.

Q: Is it normal to feel nervous or anxious when first starting MCP-ratiopharm?

Official labeling notes that the active ingredient may cause extrapyramidal symptoms, which can manifest as feelings of restlessness, agitation, or jitteriness (known as akathisia). The official product information also advises monitoring for changes in mood, including feelings of anxiety or depression. These effects are often most noticeable when starting the medication.

Q: Can MCP-ratiopharm cause involuntary chewing or lip-smacking movements?

Yes, the development of uncontrolled chewing movements, lip smacking, or rapid movements of the tongue are described in the regulatory labeling as possible signs of a serious movement disorder known as Tardive Dyskinesia. These involuntary actions are typically linked to the duration of treatment.

Q: Is MCP-ratiopharm used to treat chronic severe heartburn when other drugs have failed?

According to official prescribing information, the active ingredient is indicated for the short-term treatment of symptomatic Gastroesophageal Reflux Disease (GERD). The labeling describes this use for patients whose symptoms are not adequately managed by other, non-metoclopramide therapies. Treatment is strictly limited in duration, typically ranging from 4 to 12 weeks.

Q: Why is it sometimes prescribed as a short-term treatment of acid reflux?

MCP-ratiopharm is sometimes prescribed for the short-term treatment of acid reflux (GERD) symptoms because its active ingredient is a prokinetic agent. This pharmacological action helps to increase the muscle tone of the lower esophageal sphincter, which is the muscle that prevents stomach contents from moving back into the esophagus.

Q: How long does it usually take for the effects of MCP-ratiopharm to start working?

Regulatory labeling indicates that the onset of pharmacological action for the oral form is typically 30 to 60 minutes after taking the dose. This time frame reflects when the active ingredient usually begins to exert its effects on the body.

Q: Can MCP-ratiopharm affect the effectiveness of contraception?

Official warnings state that the active ingredient can accelerate the rate at which the stomach empties, a process called gastric motility. Because of this, it may enhance or diminish the absorption of other oral medications, which could potentially impact the effectiveness of oral contraceptive pills.

Q: Does the medicine affect a person's ability to drive or operate machinery?

Regulatory patient safety materials advise caution, as the medicine commonly causes side effects such as drowsiness, dizziness, or confusion. Regulatory materials contain warnings that advise against driving or operating heavy machinery until individuals are certain how the medication affects them and the effects have worn off.

Q: Are there reported links between MCP-ratiopharm and changes in menstrual cycles?

The active ingredient is known to cause hyperprolactinaemia, which means elevated levels of the hormone prolactin in the blood. This hormonal change is cited in regulatory documents as potentially leading to irregular menstrual cycles or, in some cases, the absence of a period.

Q: How long does the active ingredient of MCP-ratiopharm stay in the body after the last dose?

For individuals with normal kidney function, the official prescribing information notes that the active ingredient has an average elimination half-life of approximately 5 to 6 hours. This is the time it takes for half of the drug to be cleared from the body.

Q: What is the general information about potential interactions with opioid pain medications?

Official regulatory documents classify opioid pain medications as Central Nervous System (CNS) depressants. When metoclopramide is combined with these, there is an increased risk of enhanced CNS depression, which can lead to excessive drowsiness and impaired consciousness.

Q: How does MCP-ratiopharm interact with medications that have anticholinergic properties?

Regulatory information indicates that anticholinergic drugs may counteract the gastrointestinal motility effects of metoclopramide. This opposition in action may reduce the overall therapeutic effectiveness of MCP-ratiopharm.

Q: Can the medication affect blood sugar levels in patients with diabetes?

The active ingredient can affect how quickly food moves from the stomach to the intestine, which may alter a patient's glycemic control (blood sugar management). Because of this effect, official labeling notes that adjustments to the timing or dosage of insulin or other diabetes medications may be necessary.

Advertisements

How should MCP-ratiopharm be stored and disposed of?

How to Store and Dispose of MCP-ratiopharm (Metoclopramide)

The storage and disposal of this medicine must comply with official regulatory labeling to maintain its stability and safety.

Storage Requirements

  • Temperature and Environment: Store the tablets below 25°C (77°F) and do not freeze. The product must be protected from both light and moisture.
  • Child Safety: It must be stored out of the sight and reach of children.
  • Packaging: Keep the medicine in its original container.

Disposal Requirements

Expired or unused MCP-ratiopharm must not be thrown away with household trash or disposed of via wastewater. All unused medicine and waste material must be discarded according to local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of MCP-ratiopharm found in:

A-Z Index: